232 related articles for article (PubMed ID: 33481917)
1. DNA-thioguanine nucleotide as a treatment marker in acute lymphoblastic leukemia patients with NUDT15 variant genotypes.
Ju HY; Lee JW; Cho HW; Hyun JK; Ma Y; Yi ES; Yoo KH; Sung KW; Choi R; Koo HH; Lee SY
PLoS One; 2021; 16(1):e0245667. PubMed ID: 33481917
[TBL] [Abstract][Full Text] [Related]
2. Role of TPMT and ITPA variants in mercaptopurine disposition.
Gerbek T; Ebbesen M; Nersting J; Frandsen TL; Appell ML; Schmiegelow K
Cancer Chemother Pharmacol; 2018 Mar; 81(3):579-586. PubMed ID: 29387964
[TBL] [Abstract][Full Text] [Related]
3.
Puangpetch A; Tiyasirichokchai R; Pakakasama S; Wiwattanakul S; Anurathapan U; Hongeng S; Sukasem C
Pharmacogenomics; 2020 Apr; 21(6):403-410. PubMed ID: 32308129
[No Abstract] [Full Text] [Related]
4. The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia.
Moriyama T; Nishii R; Lin TN; Kihira K; Toyoda H; Jacob N; Kato M; Koh K; Inaba H; Manabe A; Schmiegelow K; Yang JJ; Hori H
Pharmacogenet Genomics; 2017 Jun; 27(6):236-239. PubMed ID: 28445187
[TBL] [Abstract][Full Text] [Related]
5. NUDT15 Variants Cause Hematopoietic Toxicity with Low 6-TGN Levels in Children with Acute Lymphoblastic Leukemia.
Yi ES; Choi YB; Choi R; Lee NH; Lee JW; Yoo KH; Sung KW; Lee SY; Koo HH
Cancer Res Treat; 2018 Jul; 50(3):872-882. PubMed ID: 28903549
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine.
Erb N; Harms DO; Janka-Schaub G
Cancer Chemother Pharmacol; 1998; 42(4):266-72. PubMed ID: 9744770
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia.
Khera S; Trehan A; Bhatia P; Singh M; Bansal D; Varma N
Cancer Chemother Pharmacol; 2019 Feb; 83(2):341-348. PubMed ID: 30474703
[TBL] [Abstract][Full Text] [Related]
8. Quantification of Thioguanine in DNA Using Liquid Chromatography-Tandem Mass Spectrometry for Routine Thiopurine Drug Monitoring in Patients With Pediatric Acute Lymphoblastic Leukemia.
Choi R; Chun MR; Park J; Lee JW; Ju HY; Cho HW; Hyun JK; Koo HH; Yi ES; Lee SY
Ann Lab Med; 2021 Mar; 41(2):145-154. PubMed ID: 33063676
[TBL] [Abstract][Full Text] [Related]
9. Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants?
Zhou H; Li L; Yang P; Yang L; Zheng JE; Zhou Y; Han Y
BMC Cancer; 2018 May; 18(1):516. PubMed ID: 29720126
[TBL] [Abstract][Full Text] [Related]
10. NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children's Cancer Center of Lebanon.
Zgheib NK; Akika R; Mahfouz R; Aridi CA; Ghanem KM; Saab R; Abboud MR; Tarek N; El Solh H; Muwakkit SA
Pediatr Blood Cancer; 2017 Jan; 64(1):146-150. PubMed ID: 27577869
[TBL] [Abstract][Full Text] [Related]
11. The Role of TPMT, ITPA, and NUDT15 Variants during Mercaptopurine Treatment of Swedish Pediatric Patients with Acute Lymphoblastic Leukemia.
Wahlund M; Nilsson A; Kahlin AZ; Broliden K; Myrberg IH; Appell ML; Berggren A
J Pediatr; 2020 Jan; 216():150-157.e1. PubMed ID: 31635813
[TBL] [Abstract][Full Text] [Related]
12. Additive effects of TPMT and NUDT15 on thiopurine toxicity in children with acute lymphoblastic leukemia across multiethnic populations.
Maillard M; Nishii R; Yang W; Hoshitsuki K; Chepyala D; Lee SHR; Nguyen JQ; Relling MV; Crews KR; Leggas M; Singh M; Suang JLY; Yeoh AEJ; Jeha S; Inaba H; Pui CH; Karol SE; Trehan A; Bhatia P; Antillon Klussmann FG; Bhojwani D; Haidar CE; Yang JJ
J Natl Cancer Inst; 2024 May; 116(5):702-710. PubMed ID: 38230823
[TBL] [Abstract][Full Text] [Related]
13. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive characterization of pharmacogenetic variants in TPMT and NUDT15 in children with acute lymphoblastic leukemia.
Moriyama T; Yang W; Smith C; Pui CH; Evans WE; Relling MV; Bhatia S; Yang JJ
Pharmacogenet Genomics; 2022 Feb; 32(2):60-66. PubMed ID: 34412101
[TBL] [Abstract][Full Text] [Related]
15. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.
Relling MV; Hancock ML; Boyett JM; Pui CH; Evans WE
Blood; 1999 May; 93(9):2817-23. PubMed ID: 10216075
[TBL] [Abstract][Full Text] [Related]
16. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K
Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948
[TBL] [Abstract][Full Text] [Related]
17. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.
Lennard L; Cartwright CS; Wade R; Richards SM; Vora A
Br J Clin Pharmacol; 2013 Jul; 76(1):125-36. PubMed ID: 23252716
[TBL] [Abstract][Full Text] [Related]
18. [Severe 6-mercaptopurine-induced hematotoxicity in childhood an ALL patient with homozygous NUDT15 missence variants].
Kimura S; Hasegawa D; Yoshimoto Y; Hirabayashi S; Hosoya Y; Yoshihara H; Kumamoto T; Tanaka Y; Manabe A
Rinsho Ketsueki; 2016 Jun; 57(6):748-53. PubMed ID: 27384855
[TBL] [Abstract][Full Text] [Related]
19. Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia.
Nielsen SN; Grell K; Nersting J; Frandsen TL; Hjalgrim LL; Schmiegelow K
Cancer Chemother Pharmacol; 2016 Nov; 78(5):983-994. PubMed ID: 27600880
[TBL] [Abstract][Full Text] [Related]
20. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism.
Bo J; Schrøder H; Kristinsson J; Madsen B; Szumlanski C; Weinshilboum R; Andersen JB; Schmiegelow K
Cancer; 1999 Sep; 86(6):1080-6. PubMed ID: 10491537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
